TESARO, Inc. (NASDAQ:TSRO)‘s stock had its “hold” rating restated by analysts at Robert W. Baird in a research note issued on Friday, November 10th. They currently have a $120.00 price objective on the biopharmaceutical company’s stock. Robert W. Baird’s price objective points to a potential upside of 43.01% from the stock’s current price.
A number of other research analysts have also recently issued reports on the company. Lake Street Capital reaffirmed a “buy” rating and issued a $143.00 price target on shares of TESARO in a report on Thursday, November 9th. HC Wainwright reissued a “buy” rating on shares of TESARO in a report on Wednesday, November 8th. Morgan Stanley reissued an “overweight” rating and set a $165.00 price objective (down from $181.00) on shares of TESARO in a report on Wednesday, November 8th. Zacks Investment Research raised TESARO from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Finally, Cann reaffirmed a “buy” rating and issued a $199.00 price target on shares of TESARO in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $161.72.
Shares of TESARO (NASDAQ:TSRO) opened at $83.91 on Friday. TESARO has a 52 week low of $83.35 and a 52 week high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. During the same quarter in the previous year, the company earned ($1.72) EPS. The firm’s revenue for the quarter was up 740.3% compared to the same quarter last year. analysts forecast that TESARO will post -8.16 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Robert W. Baird Reiterates Hold Rating for TESARO, Inc. (TSRO)” was first published by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/tesaro-inc-tsro-stock-rating-reaffirmed-by-robert-w-baird/1773859.html.
In other TESARO news, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total value of $1,465,501.04. Following the transaction, the vice president now owns 6,258 shares of the company’s stock, valued at $844,329.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director James O. Armitage sold 10,000 shares of the business’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total value of $1,171,300.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $1,171,300. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,692 shares of company stock worth $4,628,976. 40.50% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of TSRO. Janus Henderson Group PLC bought a new stake in shares of TESARO in the second quarter valued at $100,301,000. PointState Capital LP bought a new stake in shares of TESARO in the second quarter valued at $85,971,000. TimesSquare Capital Management LLC bought a new stake in shares of TESARO during the 3rd quarter valued at $33,911,000. Pictet Asset Management Ltd. raised its stake in shares of TESARO by 58.1% during the 3rd quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock valued at $81,450,000 after purchasing an additional 231,799 shares during the period. Finally, Pioneer Investment Management Inc. raised its stake in shares of TESARO by 195.6% during the 2nd quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock valued at $44,441,000 after purchasing an additional 210,273 shares during the period.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.